Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro
© Dery et al; licensee BioMed Central Ltd. 2007
- Received: 21 August 2007
- Accepted: 25 September 2007
- Published: 25 September 2007
To date, tools to study metastasis in endometrial cancers are insufficiently developed. The aim of this study was to characterize the cell line EN-1078D, a new endometrial carcinoma cell line derived from a metastasis to the ovary.
Methods and Results
Cells were characterized using cytology, transmission electron microscopy, karyotyping and morphological appearance in culture. Molecular features were determined by RT-PCR, Western Blot, FISH and sequencing. MTT proliferation assays were performed to investigate the sensitivity of EN-1078D to anticancer agents such as cisplatin and doxorubicin. Also, subcutaneous and intravenous injections in nude mice were done to test the tumorigenic and metastatic properties of EN-1078D cells. Our results indicate that EN-1078D cells express both oestrogen receptors isoforms (ER alpha and ER beta) and also low levels of progesterone receptor B (PR-B). In addition, this cell line expresses high levels of MMP-2 and MMP-14 mRNA, low levels of TIMP-1 and TIMP-2 transcripts and no detectable levels of MMP-9 mRNA. Moreover, all nude mice developed tumors by subcutaneous injections and cell invasion was observed in vitro in response to TGF-beta 3. Her-2/neu was not overamplified but mutations in the C-2 domain of PTEN gene as well as codon 12 of the K-Ras gene were found. Finally, EN-1078D shows sensitivity to drugs commonly used in chemotherapy such as cisplatin and doxorubicin: IC50 of 2.8 μM of cisplatin after 72 hours of exposure and 0.54 μM of doxorubicin after 48 hours.
Taken together, these results suggest that EN-1078D will be an excellent tool to study the properties of metastatic endometrial cancer cells in vitro and their regulation by sex steroids.
- Endometrial Cancer
- Endometrial Carcinoma
- PTEN Gene
- Endometrial Cancer Cell
- Endometrial Carcinoma Cell
Uterine cancer is the fourth commonly diagnosed cancer among women in the North America. Ninety-seven percent of all cancers of the uterus arise from the glands of the endometrium and are known as endometrial carcinomas . When diagnosed at early stages of the disease, this type of cancer is a highly curable malignancy with a 5-year relative survival rate of more than 80% . However, patients presenting metastases have a 5-year survival rate of less than 20% . Indeed, metastasis represents the main cause of death for patients with endometrial carcinoma. Very few models are available, to date, for the experimental characterization of factors involved in the metastatic phenotype in endometrial carcinoma cells.
Cell models of endometrial cancers are characterized by particular gene expressions and mutations which stratefy the disease. The cytokeratins (Ker) and other types of intermediate filaments are routinely used as indicators of tumor cell types as well as markers of differentiation , because their composition in any particular epithelium is predictable  The presence of functional steroid receptors, estrogen receptor alpha and beta (ERα and ERβ), progesterone receptor A and B (PR-A and PR-B) has been quantitatively associated with histologic differentiation , response to therapy  and metastatic potential . Sex steroid hormones influence the metastatic phenotype in cancer cells, notably by regulating adhesion/de-adhesion events, angiogenesis, cellular invasion into the basement membrane and interstitium . Therefore, the expression levels of ER and PR, as well as the impact of sex steroids are important regulators of endometrioid cells.
The uterus undergoes extensive tissue remodelling throughout each reproductive cycle and these dynamics change are regulated, in part, by the matrix metalloproteinase (MMP) system . The MMPs are a family of proteolytic enzymes that can cleave a large array of extracellular matrix (ECM) proteins as well as other cellular, non-matrix proteins. Particular MMPs (including MMP-2, MMP-9 and MMP-14) are involved in key events in cancer cells, including proliferation, apoptosis and angiogenesis [10, 11]. Importantly, loss of control of MMP activity has been linked to the malignant potential of tumors by enhancing invasion and metastasis . When present in sufficient amount, the tissue inhibitors of MMPs (TIMPs) specifically inhibit MMP activity . These interplay of these molecules are critically important in tumor metastasis.
Mutations in particular oncogenes and tumor suppressor genes can promote cancer cell development and their characteristic profile can help identify cancer cell types. Mutations in the tumor suppressor phosphatase and tensin homologue deleted on chromosome Ten (PTEN) gene can been found in approximately 50% of endometrial cancer cells [13–15]. Mutation in both PTEN gene alleles results in the expression of an inactive PTEN protein, which can not prevent activation of activated-by-kinas-tyrosine protein also called Akt and results in constitutively active Akt pathway. Since active Akt blocks the action of several pro-apoptotic proteins , apoptosis is deregulated in mutated PTEN cells. Mutational activation of K-ras (Kirsten rat sarcoma) has been observed in 10–30% of endometrioid carcinoma . Ras is a signal transducer located on the inner surface of the plasma membrane. Hyperexpression of ras results in growth stimulation, whereas point mutations at codons 12, 13, and 61 alter its structure, preventing inactivation and causing cell transformation . Amplification of Her-2/neu, a proto-oncogene with a high degree of homology to the epidermal growth factor (EGF), is associated with local invasion and tumor progression of endometrial carcinoma [19–22]. As these molecular alterations are hallmarks of endometrioid cancers, their characterization in cellular models is important. We had the opportunity to characterize a new endometrial cell line that was recently derived from an ovarian metastase, which represents a putative new tool for the study of endometrial carcinoma metastasis in vitro. We have extensively characterized this cell line in term of growth and molecular properties.
Finally, deregulated apoptotic mechanisms that allow cancer cell to proliferate and metastasize can lead to cancer cell resistance to pro-apoptotic agents such as chemotherapeutic drugs. We have characterized the response of EN-1078D cells to the main chemotherapeutic agents currently used for the treatment of endometrial cancer, cisplatin and doxorubicin. Together, this information can be applied to cellular and molecular studies in EN-1078D.
The donor of the EN-1078D cell line was a 52-year-old woman, gravida 1, para 1, menopaused since two years. Histopathological examination revealed an endometrial adenocarcinoma poorly differentiated stage IIIC, with ovarian and ganglionic metastasis. At the time of surgery, the advanced tumoral invasion of the uterus did not allow its removal and bilateral ovariectomy was done. The patient was initially treated with megestrol acetate (160 mg/day) associated with local radiotherapy (45 Gy) and endocervical curietherapy. Six years after the initial surgery, the patient is still alive without recurrence.
Histology of the original tissue and cell line establishment
The cell line was obtained from a patient of Centre Hospitalier de l'Université de Montréal and isolated from a metastase which completely replaced the ovaries. Informed consent was obtained and research studies approved by the Montreal University Institutional Review Board. The ovarian tumor consisted mainly of cells in Indian file with some glandular structures and central necrosis typical of an endometrial biopsy. At histopathological examination, immunohistochemistry analysis revealed 80% positivity staining for oestrogenic receptors and 25% for progesteronic receptors. Cells were established in culture as described previously . Briefly, tumor tissue was minced with scissors into 2–4 mm explants in OSE media (without Fetal Bovine Serum (FBS)). Enzymatic dissociation was accomplished by digestion with collagenase and aggregates were dissociated by gently pipetting. The cellular fraction was diluted 1:5 in OSE media supplemented with 10% v/v FBS and incubated undisturbed at 37°C in 5% CO2/air for 24–48 hours. After cells had adhered to the plastic, they were washed once in PBS and subsequently passaged in OSE/10% v/v FBS until the cell line was stably established. Afterwards, the cells were grown and maintained in DMEM-F12 with HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), and the medium was supplemented with 10% v/v bovine growth serum (BGS) and 50 μg/ml gentamycin. Until now, the cell line was subcultured more than a 100 passages and is preserved under cryogenic conditions (5% v/v DMSO (dimethyl sulfoxide)/culture media, in liquid nitrogen). Experiments using this cell line were carried out after long term passage (>76 passages). For experimentation without steroid hormones, the cell line was cultured at least two weeks in phenol-free DMEM-F12 supplemented with 10% v/v dextran-charcoal stripped FBS (FBS DC) and 50 μg/ml gentamycin, prior experimentation.
Morphology of the cultured cells
Cells grown in culture flasks were photographed by phase-contrast microscopy. For transmission electron microscopy study, the cells were grown to confluence in culture flasks. They were washed with 0.1 M cacodylate buffer (pH 7.4) and fixed with 2.5% v/v glutaraldehyde in cacodylate buffer for 1 hour at room temperature. After washing twice with buffer, the cell layer was delicately detached with the help of cell scraper (Costar, VWR Canlab, Mississauga, ON, CA) and was postfixed with 1% v/v osmic acid for 1 hour at room temperature. The cells were then washed in cacodylate buffer, dehydrated in graded concentrations of ethanol and embedded with Spurr overnight. After polymerization, thin sections were contrasted with 4% w/v uranyl acetate in 50% v/v methanol following by lead citrate coloration. Specimens were examined and photographed with a Phillips EM 208S electron microscope.
In Vitro growth assays
Growth curves were performed by seeding cells (1 × 105) into 42 flasks (25-cm2) in fresh culture medium (reference day 1). From day 2 to day 15, total cell numbers of 3 flasks were counted with a hemocytometer and discarded thereafter . The media was changed every 3 days. The population doubling time was calculated from the slope of the growth curve during the logarithmic phase while saturation density was determined by the plateau phase. For plating efficiency studies, one hundred cells were plated in 100-mm petri dishes. After two weeks, the colonies formed were fixed in 95% v/v ethanol and stained with methylene blue. Plating efficiency was determined by the ratio of the number of colonies (more than 50 cells) to the total number of inoculated cells . The experiments were done at each ten passages and were repeated ten times.
In vivo growth assays
Subcutaneous tumor xenografts were established in four 6-week-old nude mice (Charles River Laboratories, Lasalle, Qc, CA) by injection of 1 × 106 EN-1078D cells in 100 μL of 2 mg/mL Matrigel. (VWR, Mississauga, ON, CA). The mice were injected at both flanks near the posterior legs. The day following inoculation, mice received a subcutaneous injection of 17 β-estradiol (E2) (0.15 mg/animal in 5% cremophor and 5% ethanol saline solution) to stimulate cell proliferation. Tumor size was measured once a week using calipers. Tumor volume was calculated using the formula 0.5 × length × (width)2 . Eight weeks after injection, mice were killed and tumors were harvested. The tumors were fixed in 10% v/v formalin solution and embedded in paraffin. Tumor sections (7 μm) were mounted on polylysine-coated slides, deparaffinized, rehydrated, and then stained with haematoxylin.
Cells were treated or not with Transforming growth factor-beta3 (TGF-β3) (10 ng/ml) for 24 hours and then trypsinised and washed in fresh media with serum. Cells were then resuspended in media without serum and counted. 3 × 104 cells were plated in a Transwell® Permeable support (Costar 3432, Corning, USA) with a 8.0 μM pore size polycarbonate membrane. Prior to cell plating, a layer of BD Matrigel Low™, diluted 1:5 in fresh media without serum was prepared and solidified. Fresh media with 10% BGS was put in the well below the support. Cells were cultured for 24 hours. At the end of the assay, the cells which had adhered in the bottom of the well and/or in filter were counted. These experiments were repeated 3 times.
Repeated chromosome analyses were carried out at each ten passages to examine the in vitro chromosomal evolution of this cell line. A total of 160 metaphases spreads were photographed and the chromosome numbers in each spread were counted. Harvesting, fixation, R and G-banding of the chromosomes were induced by using classical techniques in cytogenetic. To confirm chromosome X and copy number of the Her-2/neu gene, we performed fluorescence in situ hybridization (FISH) with painting probes CEP X (DXZ1)/Y (DYZ1) alpha satellite III and Her-2 IVD Kit (Vysis/Abbott Laboratories, Mississauga, ON, CA) according to the protocols supplied by the company and analyzed the karyotype with Cytovision.
MTT proliferation assays
For drugs assay, cells were plated at a density of 1.5 × 104 cells/well in 96-wells plates, 24 hours before the assay. Cells were cultured for 24, 48 and 72 hours in the presence of increasing concentrations of cisplatin and doxorubicin (0; 0.625; 1.25; 2.5; 5; 10 and 20 μM in DMF (dimethylformamide)). HeLa, a cervical cancer cell line, which we have previously found to be sensitive to these drugs was used as positive control, while KLE, an endometrial adenocarcinoma cell line poorly inhibited by the drug, was used as negative control. For steroid hormones assays, cells cultured in phenol-free media were plated at a density of 2 × 104cells/well in 96 wells plate, 24 hours before the assay. Preliminary dose-response assays were done to determine the treatments conditions: cells were cultured for 48 hours with 10-6M of progesterone (P4) and for 24 hours with 10-7M of E2, supplemented with 1% FBD DC. At the end of the culture period, 10 μl of MTT (5 mg/ml, thiazolyl blue tetrazolium bromide) was added to each well. After 4 hours of incubation with MTT, 100 μl of solubilization solution was added (10% w/v SDS in 0.01 M HCl) and the microplate was incubated overnight (37°C, 5% CO2/air). The OD (620 nm) was read with the Fluostar Optima reader. The experiments were repeated 3 times.
Semi-quantitative RT-PCR analyses
PCR primers, cycling conditions and positive controls used.
Each reaction mixture (final volume 50:1) contained 1× Buffer, RT template or negative control (5:1), MgCl2 (50 mM), dNTPs (5 mM), primers (pM; 2,5:1 each) and Taq polymerase (5 U/μl). The PCR cycling conditions chosen were 30 sec at 94°C, 30 sec at the appropriate annealing temperature and extension time at 72°C (Table 1), followed by a 5 min extension at 72°C. Reaction products were analysed on 1% w/v agarose gels. Bands were visualized by ethidium bromide staining. β-actin was used as loading control for each experiments.
Protein extraction and Western analysis
Cells were trypsinized, lysed in lysis buffer (PBS 1× pH 7.4; 1% Nonidet P-40; 0.5% Sodium deoxycholate; 0.1% SDS; Protease Inhibitor Cocktail Tablets (Roche, Indianapolis, IN, USA), frozen and thawed three times, and centrifuged (15,700 g, 20 min at 4°C) to remove insoluble material. Supernatant was recovered and stored at -20°C pending analysis. Protein content was determined with the Bio-Rad DC Protein Assay (Bio Rad, Mississauga, ON, CA). Protein extracts (50 μg except for cytokeratines where 25 μg was used) were heated (95°C, 3 min), resolved by 8, 10 or 14% w/v SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred to nitrocellulose membranes (15 V, 30 min) using a semi-dry transfer apparatus (Bio-Rad). Membranes were then blocked (1 hr, RT) with PBS 1× containing 5% w/v non-fat milk powder, and then incubated with primary antibody (ERα: LabVision Ab15, dilution1:500, positive control MS-1071-PCL; ERβ: Labvision beta Ab-24 1:2000, positive control RB-037-PCL; PRA-B: Cell Signaling #3172 dilution 1:1000; Pan-cytokeratins: Sigma c-2562, dilution 1:75000) overnight (except for β-actin, one hour) at 4°C, and subsequently with Horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (1:4000; RT, 45 min) or with HRP-conjugated anti-mouse secondary antibody (1:2500; RT, 45 min). Peroxydase activity was visualized with the Super Femto kit (Pierce/Fisher, Nepean, ON, CA), according to the manufacturer's instructions. β-actin was used as a loading control for each experiments (Sigma A-3854 clone AC-15, dilution 1:60000, one hour).
Sequencing of the PTEN and K-ras genes
Mutation of the PTEN and K-ras gene at codons 12/13 and 61 respectively were examined by sequencing early passage EN-1078D. PTEN and K-ras gene were amplified by PCR using the following primer pairs: for PTEN, 5'-CCCAGACATGACAGCCATC-3' (forward) and 5'-TTTCATGGTGTTTTATCCCTCTT-3' (reverse); for K-ras, 5'-AGGCCTGCTGAAAATGACTG-3' (forward) and 5'-TCCTGAGCCTGTTTTGTGTCT-3' (reverse). An initial denaturation of 3 min at 94°C was followed by 35 cycles of 30 sec at 94°C, 30 sec at 58°C for K-ras/64°C for PTEN and 30 sec at 72°C for K-ras/1 min 30 for PTEN, and a final elongation step of 5 min at 72°C. PCR products were cloned in competent E. coli using pcDNA3.1/V5-His TOPO TA expression kit (Invitrogen, Burlington, On, Ca) according to the manufacturer's instructions. For sequencing, PCR products were purified with Miniprep purification kit (Qiagen, Mississauga, ON, CA). The sequencing was carried out using automatic sequencers models capillary ABI PRISM 3100 and ABI PRISM 377 in the Laboratory of Synthesis and Analysis of Nucleic Acids at Laval University (Québec, QC).
Cell morphology and growth
Molecular characterization of EN-1078D
To confirm the chromosomal complement 45, X, two probes were used: CEP X (DXZ1) and Y (DYZ1) alpha satellite III. The DXZ1 probe, with an emission wavelenght in the orange spectrum, hybridizes to the satellite DNA localized in the centromere of the X chromosome, while the DYZ1 probe, with an emission wavelenght in the green spectrum, hybridizes to the satellite DNA III localized in Yq12 locus (Fig. 5B). The results showed only one positive signal in each 988 interphasic cells analyzed. No green signal was obtained indicating that Y chromosome was not present. Figure 5C shows an interphasic hybridization carried out with a probe located on the long arm of chromosome 17q11.2q12 called Her-2/neu. To determine the number of copies of the Her-2/neu gene present in this cancer cell line, we used a probe marked with a fluorescent protein emitting in the orange spectrum which covers the complete Her-2/neu gene as well as a probe marked with fluorescent protein emitting in the green spectrum hybridizing to the satellite DNA in the centromere of chromosome 17. The analysis of 1000 cells showed that only one copy of this gene was present in chromosome 17, indicating no amplification of Her-2/neu gene in EN-1078D cells: a low level of amplification range is between 2 and 4 signals/centromere . We have found, however, other types of mutations in this cell line: sequencing revealed two sites of mutations in PTEN gene. Codon 275 is mutated by addition of a nucleotide and codon 367 replaces a valin for isoleucin. In addition, K-Ras gene analysis showed the classical G to T transversions in the codon 12 (data not shown).
Chemosensitivity of EN-1078D cell line
Constitutive expression and activity of MMPs increases the invasiveness of various types of cancer cells, and we have determined characterized the expression of MMP-2, MMP-9 and MMP-14 as well as TIMP-1 and TIMP-2 mRNA in EN-1078D cells, using RT-PCR (Fig. 8A and 8B). We found elevated levels of MMP-2 and its physiological activator, MMP-14 mRNAs (Fig. 8B), and low levels of their inhibitor TIMP-2 mRNA (Fig. 8C). As expected, we found that MMP-9 mRNA was not expressed constitutively (Fig. 8A), suggesting that external stimuli, such as contact with matrix protein in Matrigel, for instance, are required to induce the expression of the enzyme. Low levels of TIMP-1 transcript were found in EN-1078D cells (Fig. 8C).
The present study describes the characterization of a new poorly differentiated endometrial carcinoma cell line, EN-1078D, isolated from a metastasis to the ovary. Although many endometrial carcinoma cell line have demonstrated their capacities to form tumors and/or metastases in nude mice (Hec-1-A, Hec-1-B, RL-95-2 and Ishikawa) [30–32], only few endometrial cancer cell lines derived directly from metastatic cancer cells (AN3CA and KLE) [33, 34].
We have confirmed the origin of simple epithelial cells  for this cell line and the endometrial carcinoma phenotype of the metastatic tumor cells because the EN-1078D cell line was isolated from a ovary. In addition, EN-1078D analysis revealed the presence of two cell populations in this cell line which is often the case in cultures derived from tissues. The presence of only one chromosome X in both populations of EN-1078D cell line confirmed the same origin for these two populations. The differentiation in two types of cell populations by the achievement of the third chromosome 17 was the fact of malignant transformation which seems to give an advantage for in vitro growth to this cellular population compared to the other one [36, 37]. In addition, we have tested the response of EN-1078D cells to two chemotherapeutic agents commonly used: cisplatin and doxorubicin. In fact, with his high FIGO (International Federation of Gynecology and Obstetrics) grade (III), his poor differentiation and his aggressiveness, it is surprising that this cell line is so sensitive to these compounds. It is suggested that the karyotypes of the cultured cells may undergo considerable changes in vitro and some of these changes may represent the malignant transformation process of the tumor cells in vivo [35, 36].
Sex steroid receptors status is crucial in the development of endometrial cancer. EN-1078D cells show all functional sex steroid receptors except for PR-A, which is not expressed. Expression of PR-B alone, a strong regulator of proliferation [8, 38], is only seen in tumor cells  and was a feature of high-grade tumors. A study by Fujimoto and Ichigo  has reported that in all metastatic lesions of uterine endometrial cancers, the expression of PR-A mRNA was suppressed and PR-B mRNA was dominantly expressed which are in correlation with our observations. Additionally, the presence of the both ERα and ERβ in EN-1078D cells confirm that this cell line will become a very interesting tool of study because the majority of endometrial cancer cell lines available express only one of these two receptors.
Loss of progesterone responsiveness in endometrial cancer  combined with the expression of some MMPs might be related to the metastatic potential of EN-1078D cells. The level expression of MMP-2, MMP-14 and TIMP-2 in EN-1078D cell line is consistent with an endometrial cancer with high invasive potential . The team of Graesslin  has found a relation between low TIMP-2 expression and myometrial invasion, lymphovascular space involvement, and lymph node metastasis. MMP-9 is normally induced under conditions that require tissue remodelling  and is predominantly expressed by inflammatory cells of the stroma . EN-1078D cells do not express MMP-9 in basal and normal culture conditions but they may produce the enzyme in other, more physiological, conditions. Given that this cell line express constitutive levels of MMP-2 and MMP-14, and that EN-1078D cells were highly invasive in vitro, this cell line represent an important tool for the characterization and the study of the molecular and cellular mechanisms regulating endometrial carcinoma cell invasion.
In endometrial cancers, frequents lesions were observed including K-Ras and PTEN mutations and Her-2/neu amplification . Our finding that K-Ras is mutated in EN-1078D cell line is supported by many studies suggesting that the majority of mutations present in the codon 12 of K-Ras and G to T transversions were predominating in the North American population . Mutations of the Ras oncogene results in autonomous cell growth  by enhancing estrogen and antiestrogen (tamoxifen)-induced transcriptional activity of the ER activation function [49, 50]. A significant correlation was found between ER-dependent PR expression and activating K-Ras mutations suggesting that enhanced activity of the ER activation function by stimulating phosphorylation mediated through mutational activation of the Ras-MAPK cascade may be one mechanism of hormone independence of endometrial cancer .
PTEN gene is frequently mutated in endometrial cancer. We have identified to 2 sites of mutations in EN-1078D cells affecting the C-terminal domain. This domain, in which ≥ 43% of PTEN mutations occur, contains many important subdomains that are common to other signal-transducing molecules . The C2 domain (amino acids 186–351) is associated with phospholipids-binding regions  and has been identified in many proteins involved in signal transduction and membrane localization . The C-terminal tail also contains a sequence rich in proline, glutamic acid, serine and threonine (PEST sequence) (amino acids 350–375 and 379–396), which are critical for PTEN stability . PEST sequences target proteins for short intracellular half-lives and protein degradation. Paradoxically, deletion of these regions leads to decreased protein expression versus the expected increase. Nonetheless, these studies point out that the PEST regions are necessary for PTEN stability and in EN-1078D cell line the PEST region contains one mutation. PTEN antagonizes the PI3K/Akt pathway by dephosphorylating PIP3(Phosphatidylinositol (3,4,5)-trisphosphate), resulting in a decreased translocation of Akt to cellular membranes and subsequent down-regulation of Akt activation. It has been shown that expression of PTEN in cells leads to decreased levels of phospho-Akt (active form), and, therefore, to increased apoptosis [56, 57]. For example, RL-95-2 and Ishikawa endometrial cancer cells lines have a mutation in the PTEN gene and express high levels of phospho-Akt [58–60]. However, the mutated PTEN-cell line EN-1078D express weak levels of phospho-Akt (data not shown) which suggests that the simple mutation of PTEN in this cell line is not sufficient to induce constitutive Akt phosphorylation.
In conclusion, our results suggest that EN-1078D cell line is an endometrial carcinoma originating from simple epithelial cells. This tumorigenic cell line, positive for both estrogen receptor isoforms and progesterone receptor B, presents mutations in PTEN and K-Ras genes, one tumor suppressor and one oncogene frequently mutated in endometrial cancers. Moreover, EN-1078D expresses high level of MMP-2, no MMP-9 and a weak expression of TIMP-2. These cells express weak levels of phosphorylated Akt and show sensitivity to drugs commonly used in chemotherapy. EN-1078D cell line showed tumorigenic capacities in vivo and is a very aggressive cell line with high invasiveness in vitr o. EN-1078D will be a useful tool to study the mechanisms involved in the invasion of endometrial cancer cells, and their regulation by sex steroids.
The authors thank Mme Lise Porteland for the derivation of the cell line, Dr Agnès Lejeune for her assistance with transmission electron microscopy, Dr Dominique Bérubé for the cytogenetic analysis. This work has been supported by a grant from CIHR (MOP-66987). Eric Asselin holds a New Investigator award of the Canadian Institute of Health Research of Canada (CIHR) and is a chairholder of the Canada Research Chair in Molecular Gyneco-Oncology. Marie-Claude Déry is recipient of an NSERC scholarship and Céline Van Themsche recipient of an FRSQ fellowship.
- Rose PG: Endometrial carcinoma. N Engl J Med. 1996, 335: 640-649. 10.1056/NEJM199608293350907.View ArticlePubMedGoogle Scholar
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54: 8-29.View ArticlePubMedGoogle Scholar
- Cooper D, Schermer A, Sun TT: Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest. 1985, 52: 243-256.PubMedGoogle Scholar
- Omary MB, Ku NO, Liao J, Price D: Keratin modifications and solubility properties in epithelial cells and in vitro. Subcell Biochem. 1998, 31:105-40.: 105-140.Google Scholar
- Markman M: Hormonal therapy of endometrial cancer. Eur J Cancer. 2005, 41: 673-675. 10.1016/j.ejca.2004.12.008.View ArticlePubMedGoogle Scholar
- Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C: Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res. 2000, 6: 3937-3943.PubMedGoogle Scholar
- Fujimoto J, Sakaguchi H, Aoki I, Khatun S, Toyoki H, Tamaya T: Steroid receptors and metastatic potential in endometrial cancers. J Steroid Biochem Mol Biol. 2000, 75: 209-212. 10.1016/S0960-0760(00)00176-X.View ArticlePubMedGoogle Scholar
- Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP: Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol. 1993, 7: 1244-1255. 10.1210/me.7.10.1244.PubMedGoogle Scholar
- Curry TE, Osteen KG: The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev. 2003, 24: 428-465. 10.1210/er.2002-0005.View ArticlePubMedGoogle Scholar
- Goldman S, Shalev E: The role of the matrix metalloproteinases in human endometrial and ovarian cycles. Eur J Obstet Gynecol Reprod Biol. 2003, 111: 109-121. 10.1016/S0301-2115(03)00341-5.View ArticlePubMedGoogle Scholar
- Nguyen M, Arkell J, Jackson CJ: Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001, 33: 960-970. 10.1016/S1357-2725(01)00007-3.View ArticlePubMedGoogle Scholar
- Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, Stendahl U: Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol. 2004, 94: 699-704. 10.1016/j.ygyno.2004.06.028.View ArticlePubMedGoogle Scholar
- Risinger JI, Hayes AK, Berchuck A, Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997, 57: 4736-4738.PubMedGoogle Scholar
- Risinger JIFAU, Maxwell GLFAU, Chandramouli GVFAU, Jazaeri AFAU, Aprelikova OFAU, Patterson TFAU, Berchuck AFAU, Barrett JC: Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.Google Scholar
- Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997, 57: 3935-3940.PubMedGoogle Scholar
- Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH: PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998, 58: 3254-3258.PubMedGoogle Scholar
- Sherman ME: Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000, 13: 295-308. 10.1038/modpathol.3880051.View ArticlePubMedGoogle Scholar
- Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, Lamb ML, Kohman LJ, Poiesz BJ: Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999, 17: 668-675.PubMedGoogle Scholar
- Choudhury A, Kiessling R: Her-2/neu as a paradigm of a tumor-specific target for therapy. Breast Dis. 2004, 20:25-31.: 25-31.Google Scholar
- Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC: HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992, 47: 179-185. 10.1016/0090-8258(92)90103-P.View ArticlePubMedGoogle Scholar
- Lazar E, Tudose N, Lazar DC: Prognostic significance of c-erbB2 protein in endometrial cancer. Rom J Morphol Embryol. 1998, 44: 101-107.PubMedGoogle Scholar
- Rolitsky CD, Theil KS, McGaughy VR, Copeland LJ, Niemann TH: HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999, 18: 138-143.View ArticlePubMedGoogle Scholar
- Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM: Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res. 1994, 215: 303-309. 10.1006/excr.1994.1346.View ArticlePubMedGoogle Scholar
- Mobus VJ, Gerharz CD, Weikel W, Merk O, Dreher L, Kreienberg R, Moll R: Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation. Gynecol Oncol. 2001, 83: 523-532. 10.1006/gyno.2001.6425.View ArticlePubMedGoogle Scholar
- Yamada T, Ueda M, Maeda T, Okamoto Y, Miyawaki Y, Otsuki Y, Ueki M, Sugimoto O: Establishment and characterization of CA 125 producing cell line (OMC-2) originating from a human endometrial adenocarcinoma. Asia Oceania J Obstet Gynaecol. 1989, 15: 403-416.View ArticlePubMedGoogle Scholar
- Geran RI GNH: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Third Edition. 1972, National Cancer Institute, 1-87.Google Scholar
- Cianciulli AM, Guadagni F, Marzano R, Benevolo M, Merola R, Giannarelli D, Marandino F, Vocaturo G, Mariani L, Mottolese M: HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res. 2003, 22: 265-271.PubMedGoogle Scholar
- Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E: AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 2004, 94: 785-795. 10.1016/j.ygyno.2004.06.023.View ArticlePubMedGoogle Scholar
- Van Themsche C, Mathieu I, Parent S, Asselin E: Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J Biol Chem. 2007, 282: 4794-4802. 10.1074/jbc.M608497200.View ArticlePubMedGoogle Scholar
- Kuramoto H, Tamura S, Notake Y: Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol. 1972, 114: 1012-1019.PubMedGoogle Scholar
- Nishida M: The Ishikawa cells from birth to the present. Hum Cell. 2002, 15: 104-117.View ArticlePubMedGoogle Scholar
- Way DL, Grosso DS, Davis JR, Surwit EA, Christian CD: Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro. 1983, 19: 147-158. 10.1007/BF02618053.View ArticlePubMedGoogle Scholar
- DAWE CJ, BANFIELD WG, MORGAN WD, SLATICK MS, CURTH HO: GROWTH IN CONTINUOUS CULTURE, AND IN HAMSTERS, OF CELLS FROM A NEOPLASM ASSOCIATED WITH ACANTHOSIS NIGRICANS. J Natl Cancer Inst. 1964, 33:441-56.: 441-456.Google Scholar
- Richardson GS, Dickersin GR, Atkins L, MacLaughlin DT, Raam S, Merk LP, Bradley FM: KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer. Gynecol Oncol. 1984, 17: 213-230. 10.1016/0090-8258(84)90080-5.View ArticlePubMedGoogle Scholar
- Lane EB, Alexander CM: Use of keratin antibodies in tumor diagnosis. Semin Cancer Biol. 1990, 1: 165-179.PubMedGoogle Scholar
- Atkin NB: Modal DNA value and chromosome number in ovarian neoplasia. A clinical and histopathologic assessment. Cancer. 1971, 27: 1064-1073. 10.1002/1097-0142(197105)27:5<1064::AID-CNCR2820270510>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Kunzmann R, Holzel F: Karyotype alterations in human ovarian carcinoma cells during long-term cultivation and nude mouse passage. Cancer Genet Cytogenet. 1987, 28: 201-212. 10.1016/0165-4608(87)90206-8.View ArticlePubMedGoogle Scholar
- Gao J, Mazella J, Tang M, Tseng L: Ligand-activated progesterone receptor isoform hPR-A is a stronger transactivator than hPR-B for the expression of IGFBP-1 (insulin-like growth factor binding protein-1) in human endometrial stromal cells. Mol Endocrinol. 2000, 14: 1954-1961. 10.1210/me.14.12.1954.View ArticlePubMedGoogle Scholar
- Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL: Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001, 61: 4576-4582.PubMedGoogle Scholar
- Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T: Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J Steroid Biochem Mol Biol. 1997, 62: 449-454. 10.1016/S0960-0760(97)00057-5.View ArticlePubMedGoogle Scholar
- Underhill C: CD44: the hyaluronan receptor. J Cell Sci. 1992, 103: 293-298.PubMedGoogle Scholar
- Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J: Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 2004, 92: 719-725. 10.1016/j.ygyno.2003.10.038.View ArticlePubMedGoogle Scholar
- Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Darai E: Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer. 2006, 16: 1911-1917. 10.1111/j.1525-1438.2006.00717.x.View ArticlePubMedGoogle Scholar
- Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 2004, 49: 179-186. 10.1016/j.critrevonc.2003.10.008.View ArticlePubMedGoogle Scholar
- Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E: Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol. 2006, 17: 637-645. 10.1093/annonc/mdj129.View ArticlePubMedGoogle Scholar
- Deligdisch L, Holinka CF: Endometrial carcinoma: two diseases?. Cancer Detect Prev. 1987, 10: 237-246.PubMedGoogle Scholar
- Cho JY, Kim JH, Lee YH, Chung KY, Kim SK, Gong SJ, You NC, Chung HC, Roh JK, Kim BS: Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer. 1997, 79: 462-467. 10.1002/(SICI)1097-0142(19970201)79:3<462::AID-CNCR6>3.0.CO;2-K.View ArticlePubMedGoogle Scholar
- Barbacid M: ras genes. Annu Rev Biochem. 1987, 56:779-827.: 779-827. 10.1146/annurev.bi.56.070187.004023.View ArticleGoogle Scholar
- Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15: 2174-2183.PubMed CentralPubMedGoogle Scholar
- Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995, 270: 1491-1494. 10.1126/science.270.5241.1491.View ArticlePubMedGoogle Scholar
- Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW: Mutations and amplification of oncogenes in endometrial cancer. Oncology. 1999, 56: 59-65. 10.1159/000011931.View ArticlePubMedGoogle Scholar
- Waite KA, Eng C: Protean PTEN: form and function. Am J Hum Genet. 2002, 70: 829-844. 10.1086/340026.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP: Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell. 1999, 99: 323-334. 10.1016/S0092-8674(00)81663-3.View ArticlePubMedGoogle Scholar
- Rizo J, Sudhof TC: C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem. 1998, 273: 15879-15882. 10.1074/jbc.273.26.15879.View ArticlePubMedGoogle Scholar
- Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H: The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A. 1999, 96: 10182-10187. 10.1073/pnas.96.18.10182.PubMed CentralView ArticlePubMedGoogle Scholar
- Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res. 1998, 58: 5285-5290.PubMedGoogle Scholar
- Myers MP, Pass I, Batty IH, Van der KJ, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998, 95: 13513-13518. 10.1073/pnas.95.23.13513.PubMed CentralView ArticlePubMedGoogle Scholar
- Gagnon V, St Germain ME, Parent S, Asselin E: Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol. 2003, 23: 803-810.PubMedGoogle Scholar
- St Germain ME, Gagnon V, Parent S, Asselin E: Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer. 2004, 3:7.: 7-10.1186/1476-4598-3-7.View ArticleGoogle Scholar
- St Germain ME, Gagnon V, Mathieu I, Parent S, Asselin E: Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol. 2004, 24: 1311-1324.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.